New PDC article mentionning TH1902 and TH1904 4.2. PDCs in clinical trials
Although the structures of PDCs are similar to antibody-drug-conjugates (ADCs), these functional peptide conjugates offer several advantages over ADCs, including selectivity, deeper tumor penetration, rapid extravasation, and slower renal clearance. The PDC drug Lu-dotatate177 has been approved by the US Food and Drug Administration (FDA) for the treatment of gastrointestinal pancreatic neuroendocrine tumors [231]. However, there are more PDCs in the development stage, such as TH1902, a PDC with a docetaxel cargo for the treatment of triple-negative breast and ovarian cancer. TH1904, a PDC loaded with DOX, can be used to treat ovarian cancer. Both PDCs target the overexpression of sortilin 1 (SORT1) receptors in cancers, including triple-negative breast, ovarian, lung, colorectal, skin, and pancreatic [232]. Another PDC drug based on a composition called a bicycle peptide is also very popular. Bicycle peptides are usually 9–20 amino acids in length and have three cysteine residues in their sequence. These cysteine residues react with small molecule linkers to constrain the peptide into a rigid conformation. Bicycle toxin conjugate can be used as a transporter for drug molecules. The drug is attached to the bicycle peptides to ensure an unhindered conformation [233]. Several types of bicycle therapeutics have entered clinical trials for specific tumors [234] Table 5. summarizes the reported clinical research progress involving PDCs published on the US FDA website (https://www.fda.gov/).
https://www.sciencedirect.com/science/article/pii/S2666138122000160